Study S002254

Open-label, Randomised, 4 Parallel-group, Phase I Clinical Trial to Investigate BI 456906 Occupancy of Glucagon Receptors in Liver and Glucagon-like Peptide 1 Receptors in Pancreas in Comparison With Semaglutide After Administration of Radiolabeled Tracer in Male and Female Subjects With Obesity Using PET and MRI

ClinicalTrials.gov record

Registration

Registration: NCT05202353
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: SINGLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 29
Start: 2024-11-01
Primary completion: 2027-01-06
Lead sponsor: Boehringer Ingelheim
Conditions: Obesity
Interventions: DRUG:BI 456906; DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: EUDRACT_NUMBER:2021-000363-76; CTIS:2024-515417-17-00

Registered primary outcomes

Percentage of glucagon (GCG) receptors occupancy in the liver using Positron emission tomography (PET) imaging at End of Treatment (EOT) visit [up to Week 17]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.